- Home
- Mea Leber Congenital Amaurosis Market
MEA Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-499 | No of pages: 202 | Format:
Middle East and Africa leber congenital amaurosis market is projected to register a CAGR of 2.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
Middle East and Africa Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the Middle East and Africa leber congenital amaurosis market are:
Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases
Increase in pipeline products and clinical trials
Market Players:
The key market players for Middle East and Africa leber congenital amaurosis market are listed below:
Spark Therapeutics, Inc.
LKC Technologies
CENTOGENE N.V.
Optos, Metrovision
Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics)
CD Genomics
ProQR Therapeutics
OCUGEN, INC.
MeiraGTx Limited
Coave Therapeutics
IVERIC bio, Inc.
Atsena Therapeutics
Editas Medicine
Eluminex Biosciences
Okuvision
Astellas Pharma Inc.
Allergan, agtc
Gyroscope Therapeutics Limited
SparingVision
Kubota Pharmaceutical Holdings Co. Ltd.
REGENXBIO Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 44 1.1 OBJECTIVES OF THE STUDY 44 1.2 MARKET DEFINITION 44 1.3 OVERVIEW OF MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET 44 1.4 LIMITATIONS 45 1.5 MARKETS COVERED 46 2 MARKET SEGMENTATION 49 2.1 MARKETS COVERED 49 2.2 GEOGRAPHICAL SCOPE 50 2.3 YEARS CONSIDERED FOR THE STUDY 51 2.4 CURRENCY AND PRICING 51 2.5 DBMR TRIPOD DATA VALIDATION MODEL 52 2.6 MULTIVARIATE MODELLING 55 2.7 DISEASE TYPE LIFELINE CURVE 55 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56 2.9 DBMR MARKET POSITION GRID 57 2.10 MARKET END USER COVERAGE GRID 58 2.11 VENDOR SHARE ANALYSIS 59 2.12 SECONDARY SOURCES 60 2.13 ASSUMPTIONS 60 3 EXECUTIVE SUMMARY 61 4 PREMIUM INSIGHTS 64 4.1 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA LEBER CONGENTIAL AMAUROSIS MARKET 66 4.2 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 68 4.3 PESTEL ANALYSIS 71 4.4 PORTERS FIVE FORCES 72 5 EPIDEMIOLOGY 73 6 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 74 6.1 DRIVERS 76 6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 76 6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 79 6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 85 6.2 RESTRAINTS 86 6.2.1 LACK OF QUALIFIED PROFESSIONALS 86 6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 87 6.3 OPPORTUNITIES 88 6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 88 6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 88 6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 89 6.4 CHALLENGES 90 6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 90 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 90 7 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 91 7.1 OVERVIEW 92 7.2 INFANTILE TYPE 95 7.3 JUVENILE TYPE 95 7.4 OTHERS 96 8 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 97 8.1 OVERVIEW 98 8.2 THERAPY 101 8.2.1 GENE THERAPY 102 8.2.1.1 LUXTURNA 102 8.2.2 RETINAL PROSTHETIC 102 8.2.3 NEUROPROTECTIVE AGENTS 102 8.2.3.1 VITAMIN A PALMITATE 103 8.2.3.2 DOCOSAHEXAENOIC ACID 103 8.2.3.3 LUTEIN 103 8.2.3.4 OTHERS 103 8.2.4 OTHERS 103 8.3 DIAGNOSIS 104 8.3.1 CLINICAL DIAGNOSIS 105 8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 105 8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 106 8.3.1.1.2 DARK ADAPTOMETRY (DA) 106 8.3.1.2 RETINAL IMAGING 106 8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 106 8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 107 8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 107 8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 107 8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 107 8.3.1.3 VISUAL FIELD TEST 107 8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 107 8.3.1.3.2 MANUAL FIELD TEST 107 8.3.1.4 CLINICAL EYE EXAMINATION 108 8.3.1.4.1 SLIT LAMP 108 8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 108 8.3.1.4.3 REFRACTION TEST 108 8.3.1.4.4 DILATION EXAM 108 8.3.1.5 OTHERS 108 8.3.2 GENETIC DIAGNOSIS 109 9 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 110 9.1 OVERVIEW 111 9.2 HOSPITALS 114 9.3 SPECIALITY CLINICS 115 9.4 AMBULATORY SURGICAL CENTERS 116 9.5 HOME HEALTHCARE 117 9.6 OTHERS 118 10 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 119 10.1 OVERVIEW 120 10.2 RETAIL SALES 123 10.2.1.1 HOSPITAL PHARMACIES 124 10.2.1.2 RETAIL PHARMACIES 124 10.2.1.3 OTHERS 124 10.3 DIRECT TENDER 124 11 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 125 11.1 MIDDLE EAST AND AFRICA 126 11.1.1 SOUTH AFRICA 133 11.1.2 SAUDI ARABIA 137 11.1.3 U.A.E 141 11.1.4 ISRAEL 145 11.1.5 EGYPT 149 11.1.6 KUWAIT 153 11.1.7 REST OF MIDDLE EAST AND AFRICA 157 12 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 158 12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 158 13 SWOT ANALYSIS 159 14 COMPANY PROFILE 160 14.1 SPARK THERAPEUTICS, INC 160 14.1.1 COMPANY SNAPSHOT 160 14.1.2 COMPANY SHARE ANALYSIS 160 14.1.3 PRODUCT PORTFOLIO 161 14.1.4 RECENT DEVELOPMENT 161 14.1.4.1 EU AUTHORIZATION 161 14.2 OPTOS 162 14.2.1 COMPANY SNAPSHOT 162 14.2.2 COMPANY SHARE ANALYSIS 162 14.2.3 PRODUCT PORTFOLIO 163 14.2.4 RECENT DEVELOPMENT 163 14.2.4.1 PRODUCT APPROVAL 163 14.3 CD GENOMICS 164 14.3.1 COMPANY SNAPSHOT 164 14.3.2 COMPANY SHARE ANALYSIS 164 14.3.3 PRODUCT PORTFOLIO 165 14.3.4 RECENT DEVELOPMENT 165 14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 166 14.4.1 COMPANY SNAPSHOT 166 14.4.2 REVENUE ANALYSIS 166 14.4.3 COMPANY SHARE ANALYSIS 167 14.4.4 PRODUCT PORTFOLIO 167 14.4.5 RECENT DEVELOPMENTS 167 14.4.5.1 COLLABORATION 167 14.5 LKC TECHNOLOGIES, INC 168 14.5.1 COMPANY SNAPSHOT 168 14.5.2 COMPANY SHARE ANALYSIS 168 14.5.3 PRODUCT PORTFOLIO 169 14.5.4 RECENT DEVELOPMENT 169 14.5.4.1 PRODUCT APPROVAL 169 14.5.5 PRODUCT APPROVAL 169 14.6 AGTC 170 14.6.1 COMPANY SNAPSHOT 170 14.6.2 REVENUE ANALYSIS 170 14.6.3 PRODUCT PORTFOLIO 171 14.6.4 RECENT DEVELOPMENTS 171 14.6.4.1 AGREEMENT 171 14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 172 14.7.1 COMPANY SNAPSHOT 172 14.7.2 REVENUE ANALYSIS 172 14.7.3 PRODUCT PORTFOLIO 173 14.7.4 RECENT DEVELOPMENTS 173 14.8 ASTELLAS PHARMA INC. 174 14.8.1 COMPANY SNAPSHOT 174 14.8.2 REVENUE ANALYSIS 174 14.8.3 PRODUCT PORTFOLIO 175 14.8.4 RECENT DEVELOPMENT 175 14.9 ATSENA THERAPEUTICS 176 14.9.1 COMPANY SNAPSHOT 176 14.9.2 PRODUCT PORTFOLIO 176 14.9.3 RECENT DEVELOPMENT 176 14.10 CENTOGENE N.V. 177 14.10.1 COMPANY SNAPSHOT 177 14.10.2 REVENUE ANALYSIS 177 14.10.3 PRODUCT PORTFOLIO 178 14.10.4 RECENT DEVELOPMENT 178 14.10.4.1 PRODUCT LAUNCH 178 14.11 COAVE THERAPEUTICS 179 14.11.1 COMPANY SNAPSHOT 179 14.11.2 PRODUCT PORTFOLIO 179 14.11.3 RECENT DEVELOPMENT 179 14.12 EDITAS MEDICINE 180 14.12.1 COMPANY SNAPSHOT 180 14.12.2 REVENUE ANALYSIS 180 14.12.3 PRODUCT PORTFOLIO 181 14.12.4 RECENT DEVELOPMENTS 181 14.12.4.1 DATA & TRAIL DATA PRESENTATION 181 14.13 ELUMINEX BIOSCIENCES 182 14.13.1 COMPANY SNAPSHOT 182 14.13.2 PRODUCT PORTFOLIO 182 14.13.3 RECENT DEVELOPMENT 182 14.14 GYROSCOPE THERAPEUTICS LIMITED 183 14.14.1 COMPANY SNAPSHOT 183 14.14.2 PRODUCT PORTFOLIO 183 14.14.3 RECENT DEVELOPMENTS 183 14.15 INVITAE CORPORATION 185 14.15.1 COMPANY SNAPSHOT 185 14.15.2 REVENUE ANALYSIS 185 14.15.3 PRODUCT PORTFOLIO 186 14.15.4 RECENT DEVELOPMENTS 186 14.15.4.1 NEW FACILITY 186 14.15.4.2 EXPANSION 186 14.16 IVERIC BIO. 187 14.16.1 COMPANY SNAPSHOT 187 14.16.2 PRODUCT PORTFOLIO 187 14.16.3 RECENT DEVELOPMENT 187 14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 188 14.17.1 COMPANY SNAPSHOT 188 14.17.2 REVENUE ANALYSIS 188 14.17.3 PRODUCT PORTFOLIO 189 14.17.4 RECENT DEVELOPMENTS 189 14.18 MEIRAGTX LIMITED 190 14.18.1 COMPANY SNAPSHOT 190 14.18.2 PRODUCT PORTFOLIO 190 14.18.3 RECENT DEVELOPMENT 190 14.19 METROVISION 192 14.19.1 COMPANY SNAPSHOT 192 14.19.2 PRODUCT PORTFOLIO 192 14.19.3 RECENT DEVELOPMENT 192 14.19.3.1 FDA CLEARANCE APPROVAL 192 14.20 OCUGEN INC. 193 14.20.1 COMPANY SNAPSHOT 193 14.20.2 PRODUCT PORTFOLIO 193 14.20.3 RECENT DEVELOPMENT 193 14.21 OKUVISION 194 14.21.1 COMPANY SNAPSHOT 194 14.21.2 PRODUCT PORTFOLIO 194 14.21.3 RECENT DEVELOPMENTS 194 14.21.3.1 APPROVAL 194 14.22 PROQR THERAPEUTICS 195 14.22.1 COMPANY SNAPSHOT 195 14.22.2 PRODUCT PORTFOLIO 195 14.22.3 RECENT DEVELOPMENTS 195 14.23 REGENXBIO INC. 196 14.23.1 COMPANY SNAPSHOT 196 14.23.2 REVENUE ANALYSIS 196 14.23.3 PRODUCT PORTFOLIO 197 14.23.4 RECENT DEVELOPMENTS 197 14.24 SPARINGVISION 198 14.24.1 COMPANY SNAPSHOT 198 14.24.2 PRODUCT PORTFOLIO 198 14.24.3 RECENT DEVELOPMENTS 198 15 QUESTIONNAIRE 199 16 RELATED REPORTS 202Segmentation
Short Description Middle East and Africa Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029. Market Definition: Leber congenital amaurosis (LCA) is a part of the spectrum of early-onset retinal dystrophy (EORD). It usually presents in the first few years of life, most often before the age of 1 year. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. Market Segmentation: Middle East and Africa leber congenital amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel. On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others. On the basis of type, the leber congenital amaurosis market is segmented into diagnosis and therapy. On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others. On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others. Market Players The key market players for Middle East and Africa leber congenital amaurosis market are listed below: Invitae Corporation Spark Therapeutics, Inc. LKC TECHNOLOGIES, INC CENTOGENE N.V. Optos, Metrovision Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics) CD Genomics ProQR Therapeutics OCUGEN, INC. MeiraGTx Limited Coave Therapeutics IVERIC bio, Inc. Atsena Therapeutics Editas Medicine Eluminex Biosciences Okuvision Astellas Pharma Inc. Allergan (A Subsidiary of Abbvie Inc.) AGTC Gyroscope Therapeutics Limited SparingVision Kubota Pharmaceutical Holdings Co. Ltd. REGENXBIO IncMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.